Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.22.2.2
Consolidated Statements of Loss and Comprehensive Loss - CAD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Expenses      
Stock-based compensation (Notes 12, 13 and 16) $ 8,035,506
Professional fees 698,209 174,211 57,272
Directors’ and officers’ consulting fees (Note 16) 687,585 200,858 118,700
Insurance expense 681,504
Transfer agent and regulatory fees 236,926 22,244 3,885
Consulting fees 220,890 34,399 43,255
Interest on loan and debentures (Notes 8 and 9) 167,873 140,264
General and administrative expenses 129,415 8,254 20,626
Travel expenses 112,074 957
Amortization of transaction costs (Note 9) 56,512 13,284
Research expenses 33,733
Bank fees and interest 9,343 2,084 2,669
Total Expenses (11,069,570) (595,598) (247,364)
Other Income      
Gain on change in fair value of derivative liabilities (Note 10) 1,103,839 32,676
Grant income (Note 20) 109,745
Recovery of accounts payable 10,740
Recovery of flow through share liability 71,249
Foreign exchange gain (loss) 409,532 (254) (6,001)
Total other income 1,623,116 43,162 65,248
Net Loss and Comprehensive Loss $ (9,446,454) $ (552,436) $ (182,116)
Weighted Average Number of Outstanding Shares      
Basic and diluted (Note 15) (in Shares) 15,884,041 13,008,669 13,007,995
Net Loss per Share      
Basic and diluted (Note 15) (in Dollars per share) $ (0.6) $ (0.04) $ (0.01)